Jeremy G. Chadwick - 02 Mar 2026 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Signature
/s/ Bruce Jacobs, as Attorney-in-Fact
Issuer symbol
KYMR
Transactions as of
02 Mar 2026
Net transactions value
-$515,594
Form type
4
Filing time
04 Mar 2026, 18:00:09 UTC
Previous filing
23 May 2025
Next filing
11 Mar 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Chadwick Jeremy G Chief Operating Officer C/O KYMERA THERAPEUTICS, INC., 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN /s/ Bruce Jacobs, as Attorney-in-Fact 04 Mar 2026 0001388406

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYMR Common Stock Award +12,575 +19% $0.000000* 79,768 02 Mar 2026 Direct F1, F2
transaction KYMR Common Stock Sale $48,175 -549 -0.69% $87.75 79,219 02 Mar 2026 Direct F3, F4
transaction KYMR Common Stock Sale $33,896 -383 -0.48% $88.50 78,836 02 Mar 2026 Direct F3, F5
transaction KYMR Common Stock Sale $99,251 -1,107 -1.4% $89.66 77,729 02 Mar 2026 Direct F3, F6
transaction KYMR Common Stock Sale $33,095 -394 -0.51% $84.00 77,335 04 Mar 2026 Direct F3, F7
transaction KYMR Common Stock Sale $171,518 -2,017 -2.6% $85.04 75,318 04 Mar 2026 Direct F3, F8
transaction KYMR Common Stock Sale $98,648 -1,150 -1.5% $85.78 74,168 04 Mar 2026 Direct F3, F9
transaction KYMR Common Stock Sale $31,012 -358 -0.48% $86.62 73,810 04 Mar 2026 Direct F3, F10

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYMR Stock Option (Right to Buy) Award +25,150 $0.000000* 25,150 02 Mar 2026 Common Stock 25,150 $90.10 Direct F11
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 3, 2025, subject to the reporting person's continued employment through each vesting date.
F2 This number includes 773 shares and shares acquired under the Registrant's employee stock purchase plan.
F3 Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.11 to $88.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.11 to $89.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.17 to $90.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.36 to $84.3338, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.4475 to $85.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.45 to $86.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.48 to $86.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11 The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date.